IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease
IL-17 e IL-17R: una diana terapéutica favorable para la enfermedad psoriásica
Read
4564
Timeswas read the article
3002
Total PDF
1562
Total HTML
Share statistics
array:22 [ "pii" => "S0001731014700158" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70015-8" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70015" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2014" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:21-33" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 770 "formatos" => array:3 [ "EPUB" => 32 "HTML" => 273 "PDF" => 465 ] ] "itemSiguiente" => array:17 [ "pii" => "S000173101470016X" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70016-X" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70016" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:34-40" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 928 "formatos" => array:3 [ "EPUB" => 33 "HTML" => 293 "PDF" => 602 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "IL-17 and infections" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "34" "paginaFinal" => "40" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "IL-17 e infecciones" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Y. Ling, A. Puel" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Y." "apellidos" => "Ling" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Puel" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101470016X?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S000173101470016X/v1_201411120051/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0001731014700146" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70014-6" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70014" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:9-20" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1123 "formatos" => array:3 [ "EPUB" => 36 "HTML" => 327 "PDF" => 760 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Pathogenic role of IL-17 in psoriasis and psoriatic arthritis" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "9" "paginaFinal" => "20" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel patógeno de la IL-17 en la psoriasis y en la artritis psoriásica" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Chiricozzi" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Chiricozzi" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700146?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700146/v1_201411120051/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "21" "paginaFinal" => "33" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. Mitra, S.K. Raychaudhuri, S.P. Raychaudhuri" "autores" => array:3 [ 0 => array:3 [ "nombre" => "A." "apellidos" => "Mitra" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 1 => array:3 [ "nombre" => "S.K." "apellidos" => "Raychaudhuri" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:4 [ "nombre" => "S.P." "apellidos" => "Raychaudhuri" "email" => array:1 [ 0 => "sraychaudhuri@ucdavis.edu" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "VA Medical Center Sacramento, Mather, CA, USA" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "University of California, Davis, School of Medicine, Internal Medicine/Rheumatology, Allergy & Clinical Immunology, Davis, CA, USA" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "University of California, Davis, Dermatology, School of Medicine, Sacramento, CA, USA" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "IL-17 e IL-17R: una diana terapéutica favorable para la enfermedad psoriásica" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec360877" "palabras" => array:4 [ 0 => "Th17" 1 => "IL-17" 2 => "Psoriasis" 3 => "Psoriatic arthritis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec360876" "palabras" => array:4 [ 0 => "Th17" 1 => "IL-17" 2 => "Psoriasis" 3 => "Artritis psoriásica" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The continuous discovery of new T cell subpopulations in human autoimmune diseases is making the immunopathological network more complex. Th17 cells are one such newly identified subset of T cells, characterized by the production of signature cytokine IL-17. In last few years, several studies have strongly established the regulatory role of Th17 cells and its signature cytokine IL-17 in autoimmune diseases including psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus and multiple sclerosis. Psoriasis and PsA are immune mediated hyperproliferative diseases, affecting skin and joint respectively. Before the discovery of Th17 cells, psoriasis and psoriatic diseases were thought to be chiefly Th1 mediated diseases; later on IL-17 knockout animal studies as well as human experimental data indicate the crucial role of Th17 cells and its signature cytokine IL-17 in the pathogenesis of these diseases. In vitro human studies have shown the abundance of Th17 cells in the psoriatic plaques. Subsequently our research group has extended this observation in psoriatic arthritis and found the abundance of CD4+IL-17+ T cells in the synovial fluid and majority of these T cells are of memory phenotype (CD4RO+CD45RA-CD11a+). In addition, we showed the significant presence of functional IL-17 receptor in synovial fibroblast of psoriatic arthritis patients. Considering the strong association of IL-17 and psoriatic disease, IL-17 targeted therapy have shown promises in preclinical and clinical trials. In this review article, we have discussed the pathogenic role of IL-17 in psoriatic disease and summarized the therapeutic efficacy and safety profile of different anti IL-17 therapy as an anti-psoriatic agent.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El descubrimiento continuo de nuevas subpoblaciones de células T en las enfermedades autoinmunes humanas está haciendo el sistema inmunopatológico más complejo. Las células Th17 son uno de los subgrupos de células T nuevamente identificados, caracterizadas por la producción de citocina IL-17. En los últimos años, muchos estudios han establecido fuertemente el papel regulador de las células Th17 y su distintiva citocina IL-17 en enfermedades autoinmunes como psoriasis, artritis psoriásica, artritis reumatoide, enfermedad intestinal inflamatoria, lupus eritematoso sistémico y esclerosis múltiple. La psoriasis y la artritis psoriásica son enfermedades hiperproliferativas mediadas inmunológicamente, que afectan la piel y la articulación, respectivamente. Antes del descubrimiento de las células Th17, se pensaba que la psoriasis y las enfermedades psoriásicas eran enfermedades medidas principalmente por Th1; más tarde, el impacto de los estudios en animales sobre la IL-17, así como los datos experimentales en humanos, indican el papel crucial de las células th17 y su distintiva citocina en la patogénesis de estas enfermedades. Los estudios humanos in vitro han mostrado la abundancia de células Th17 en las placas psoriásicas. Posteriormente, nuestro grupo de investigación ha prolongado esta observación en la artritis psoriásica y ha encontrado abundancia de CD4 + IL-17 + células T en el líquido sinovial; la mayoría de estas células T son de fenotipo de memoria (CD4RO+CD45RA-CD11a+). Además, hemos demostrado la presencia significativa del receptor funcional de IL-17 en los fibroblastos sinoviales de los pacientes con artritis psoriásica. Teniendo en cuenta la potente asociación de la Il-17 y la enfermedad psoriásica, la terapia enfocada en la IL-17 ha mostrado ser prometedora en estudios preclínicos y clínicos. En este artículo de revisión hemos analizado el papel patogénico de la IL-17 en la enfermedad psoriásica y hemos resumido la eficacia terapéutica y el perfil de seguridad de una terapia anti IL-17 diferente como agente antipsoriásico.</p>" ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700158/v1_201411120051/en/main.assets" "Apartado" => array:4 [ "identificador" => "6148" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/00000105000000S1/v1_201411120051/S0001731014700158/v1_201411120051/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700158?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 2 | 9 | 11 |
| 2024 October | 34 | 65 | 99 |
| 2024 September | 24 | 51 | 75 |
| 2024 August | 42 | 85 | 127 |
| 2024 July | 26 | 44 | 70 |
| 2024 June | 38 | 32 | 70 |
| 2024 May | 25 | 42 | 67 |
| 2024 April | 31 | 37 | 68 |
| 2024 March | 24 | 39 | 63 |
| 2024 February | 34 | 59 | 93 |
| 2024 January | 20 | 40 | 60 |
| 2023 December | 20 | 26 | 46 |
| 2023 November | 33 | 35 | 68 |
| 2023 October | 21 | 26 | 47 |
| 2023 September | 21 | 41 | 62 |
| 2023 August | 20 | 26 | 46 |
| 2023 July | 23 | 39 | 62 |
| 2023 June | 25 | 34 | 59 |
| 2023 May | 21 | 52 | 73 |
| 2023 April | 14 | 22 | 36 |
| 2023 March | 19 | 46 | 65 |
| 2023 February | 17 | 31 | 48 |
| 2023 January | 17 | 31 | 48 |
| 2022 December | 25 | 30 | 55 |
| 2022 November | 22 | 28 | 50 |
| 2022 October | 15 | 25 | 40 |
| 2022 September | 20 | 44 | 64 |
| 2022 August | 16 | 48 | 64 |
| 2022 July | 17 | 94 | 111 |
| 2022 June | 36 | 49 | 85 |
| 2022 May | 53 | 71 | 124 |
| 2022 April | 30 | 54 | 84 |
| 2022 March | 36 | 78 | 114 |
| 2022 February | 19 | 46 | 65 |
| 2022 January | 23 | 63 | 86 |
| 2021 December | 18 | 42 | 60 |
| 2021 November | 16 | 47 | 63 |
| 2021 October | 32 | 61 | 93 |
| 2021 September | 23 | 70 | 93 |
| 2021 August | 25 | 56 | 81 |
| 2021 July | 23 | 70 | 93 |
| 2021 June | 16 | 52 | 68 |
| 2021 May | 26 | 71 | 97 |
| 2021 April | 16 | 81 | 97 |
| 2021 March | 27 | 45 | 72 |
| 2021 February | 14 | 57 | 71 |
| 2021 January | 22 | 42 | 64 |
| 2020 December | 15 | 38 | 53 |
| 2020 November | 28 | 54 | 82 |
| 2020 October | 5 | 22 | 27 |
| 2020 September | 13 | 28 | 41 |
| 2020 August | 12 | 28 | 40 |
| 2020 July | 13 | 31 | 44 |
| 2020 June | 23 | 27 | 50 |
| 2020 May | 23 | 27 | 50 |
| 2020 April | 15 | 20 | 35 |
| 2020 March | 21 | 26 | 47 |
| 2019 May | 1 | 0 | 1 |
| 2018 December | 0 | 2 | 2 |
| 2018 September | 1 | 2 | 3 |
| 2018 March | 1 | 1 | 2 |
| 2018 February | 10 | 17 | 27 |
| 2018 January | 13 | 14 | 27 |
| 2017 December | 12 | 21 | 33 |
| 2017 November | 15 | 22 | 37 |
| 2017 October | 5 | 17 | 22 |
| 2017 September | 10 | 20 | 30 |
| 2017 August | 10 | 10 | 20 |
| 2017 July | 17 | 11 | 28 |
| 2017 June | 24 | 22 | 46 |
| 2017 May | 16 | 18 | 34 |
| 2017 April | 18 | 27 | 45 |
| 2017 March | 20 | 25 | 45 |
| 2017 February | 8 | 21 | 29 |
| 2017 January | 15 | 34 | 49 |
| 2016 December | 20 | 17 | 37 |
| 2016 November | 22 | 17 | 39 |
| 2016 October | 30 | 16 | 46 |
| 2016 July | 1 | 1 | 2 |
| 2016 June | 0 | 8 | 8 |
| 2016 May | 0 | 9 | 9 |
| 2016 April | 0 | 5 | 5 |
| 2016 March | 0 | 3 | 3 |
| 2016 February | 0 | 12 | 12 |
| 2016 January | 0 | 3 | 3 |
| 2015 December | 0 | 17 | 17 |
| 2015 November | 0 | 11 | 11 |
| 2015 October | 0 | 13 | 13 |
| 2015 September | 0 | 11 | 11 |
| 2015 August | 0 | 10 | 10 |
| 2015 July | 0 | 8 | 8 |
| 2015 June | 0 | 8 | 8 |
| 2015 May | 0 | 6 | 6 |
| 2015 April | 0 | 1 | 1 |
| 2015 March | 0 | 4 | 4 |
| 2015 February | 2 | 1 | 3 |
| 2014 December | 1 | 0 | 1 |
| 2014 November | 1 | 0 | 1 |
Show all
